MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant
Sanaria Inc., a privately held company in Rockville, Maryland, and the University of Maryland Biotechnology Institute (UMBI) announced the receipt of a multi-year Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Malaria vaccine developer Sanaria Inc. receives the Technology Council of Maryland’s Emerging Company of the Year Award.
Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland’s Tech Awards Celebration honoring the state’s technology leaders and organizations.
Self-Experimenters: Malaria Vaccine Maven Baits Irradiated Mosquitoes with His Own Arm
Stephen Hoffman has given years of sweat—and lots of blood—on his quest to stop a global killer. Read the full article in Scientific American.
Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement
Today Top Institute Pharma announces a highly promising research project that is aimed at the development of a malaria vaccine. This TI Pharma project will be an expansion of extremely promising findings from previous studies.
Sanaria featured in The New York Times, The Soul of a New Vaccine
The sign on the wall reads “Emergency Response Procedures for a Mosquito Release.” Among them are “Do Not Leave the Room or Open Any Doors!!!” and “Do Not Panic!” Everything in the room is white, including the lab coats and surgical masks — for sterility, yes, but also the better to see a mosquito. Hanging next to the sign, in vivid Coast Guard orange, is the last line of defense, a brace of fly swatters. This room, the mosquito dissection lab, in an unassuming biotech park in the Washington suburbs, is at the heart of one of the most controversial ideas in vaccine science. Sanaria Inc. (meaning “healthy air,” a play on the Italian “mal’aria” or “bad air”) is making a vaccine the old-fashioned way, more or less as Louis Pasteur did. Read the full article and see the photos in The New York Times.
Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on Al Jazeera English’s: The Pulse
Despite millions of dollars being spent on research there is no vaccine available against one of the world's biggest killer diseases -- Malaria. The Pulse looks at the parasite that has proved too complex for scientists and visits a clinical trial in Tanzania, which is showing unusual promise.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.